EUVIMEDEUVIMED entdecken
Crossref

Development of a centrifugal bioreactor for rapid expansion of CD8 cytotoxic T cells for use in cancer immunotherapy

Kitana M Kaiphanliam iD, Brenden Fraser-Hevlin iD, Eric S Barrow iD, William C Davis iD, Bernard J Van Wie iD

Biotechnology Progress · 2023

DOI: 10.1002/btpr.3388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Progress, 2023. Verfasst von Kitana M Kaiphanliam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Voiland School of Chemical Engineering and Bioengineering, Washington State University, Pullman, Washington, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Cytotoxic, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Science Foundation, Washington Research Foundation, Washington State University (Commercialization Gap Fund 2021, Palouse Club Cougar Cage 2021).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One of the current difficulties limiting the use of adoptive cell therapy (ACT) for cancer treatment is the lack of methods for rapidly expanding T cells. As described in the present report, we developed a centrifugal bioreactor (CBR) that may resolve this manufacturing bottleneck. The CBR operates in perfusion by balancing centrifugal forces with a continuous feed of fresh medium, preventing cells from leaving the expansion culture chamber while maintaining nutrients for growth. A bovine CD8 cytotoxic T lymphocyte (CTL) cell line specific for an autologous target cell infected with a protozoan parasite, Theileria parva , was used to determine the efficacy of the CBR for ACT purposes. Batch culture experiments were conducted to predict how CTLs respond to environmental changes associated with consumption of nutrients and production of toxic metabolites, such as ammonium and lactate. Data from these studies were used to develop a kinetic growth model, allowing us to predict CTL growth in the CBR and determine the optimal operating parameters. The model predicts the maximum cell density the CBR can sustain is 5.5 × 10 7 cells/mL in a single 11‐mL conical chamber with oxygen being the limiting factor. Experimental results expanding CTLs in the CBR are in 95% agreement with the kinetic model. The prototype CBR described in this report can be used to develop a CBR for use in cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, CytotoxicNeoplasmsAnimalsCattleCD8-Positive T-LymphocytesCell LineImmunotherapyBioreactors

Stichwörter der Autor:innen

T cellsbiomanufacturingbioprocessingimmunotherapymammalian cell kinetics

Autor:innen und Institutionen

  • Voiland School of Chemical Engineering and Bioengineering, Washington State University, Pullman, Washington, USA.
  • Voiland College of Engineering and Architecture Professional Shops, Washington State University, Pullman, Washington, USA.
  • Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, Washington, USA.

ORCID-Profile: Kitana M Kaiphanliam, Brenden Fraser-Hevlin, Eric S Barrow, William C Davis, Bernard J Van Wie

Förderung

  • National Science Foundation
  • Washington Research Foundation
  • Washington State University (Commercialization Gap Fund 2021, Palouse Club Cougar Cage 2021)

Zitieren

APA

Kaiphanliam, K. M., Fraser-Hevlin, B., Barrow, E. S., Davis, W. C., & Van Wie, B. J. (2023). Development of a centrifugal bioreactor for rapid expansion of CD8 cytotoxic T cells for use in cancer immunotherapy. Biotechnology Progress. https://doi.org/10.1002/btpr.3388

Vancouver

Kaiphanliam KM, Fraser-Hevlin B, Barrow ES, Davis WC, Van Wie BJ. Development of a centrifugal bioreactor for rapid expansion of CD8 cytotoxic T cells for use in cancer immunotherapy. Biotechnology Progress. 2023. doi:10.1002/btpr.3388

BibTeX
@article{Kaiphanliam2023,
  author = {Kaiphanliam, Kitana M and Fraser-Hevlin, Brenden and Barrow, Eric S and Davis, William C and Van Wie, Bernard J},
  title = {Development of a centrifugal bioreactor for rapid expansion of CD8 cytotoxic T cells for use in cancer immunotherapy},
  journal = {Biotechnology Progress},
  year = {2023},
  doi = {10.1002/btpr.3388}
}
Kostenlos starten →